Semi-quantitative measurement of asymptomatic L. infantum infection and symptomatic visceral leishmaniasis in dogs using Dual-Path Platform® CVL

Mandy Larson; Angela Toepp; Benjamin Scott; Melissa Kurtz; Hailie Fowler; Javan Esfandiari; Randall F Howard; Aarthy C Vallur; Malcolm S Duthie; Christine Petersen; EPID:158:001

doi:10.1007/s00253-016-7925-6

Back

Semi-quantitative measurement of asymptomatic L. infantum infection and symptomatic visceral leishmaniasis in dogs using Dual-Path Platform® CVL

Journal article

Open access

Peer reviewed

Semi-quantitative measurement of asymptomatic L. infantum infection and symptomatic visceral leishmaniasis in dogs using Dual-Path Platform® CVL

Mandy Larson, Angela Toepp, Benjamin Scott, Melissa Kurtz, Hailie Fowler, Javan Esfandiari, Randall F Howard, Aarthy C Vallur, Malcolm S Duthie, Christine Petersen, …

Applied microbiology and biotechnology, Vol.101(1), pp.381-390

01/2017

DOI: 10.1007/s00253-016-7925-6

PMCID: PMC6500589

PMID: 27796441

Files and links (1)

url

https://doi.org/10.1007/s00253-016-7925-6View

Published (Version of record) Open Access

Abstract

Infection with Leishmania causes diseases with variable presentation. The most severe form is visceral leishmaniasis (VL), caused by either L. donovani or L. infantum. Despite efforts to eliminate VL, to date, molecular detection in resource-poor settings have lacked the accuracy and rapidity that would enable widespread field use and the need for accurate, sensitive assays to detect asymptomatic Leishmania infection has become apparent. The domestic dog serves as the primary reservoir host of L. infantum. Study of this reservoir population provides an opportunity to evaluate the sensitivity and specificity of diagnostics for well-defined, symptomatic, canine visceral leishmaniasis (CVL) and asymptomatic L. infantum infection. Blood samples from an L. infantum-endemic population of US hunting dogs were evaluated with Dual-Path Platform (DPP®) CVL compared to those obtained via direct detection methods (culture- and Leishmania-specific quantitative polymerase chain reaction, qPCR) and immunofluorescence anti-Leishmania antibody test (IFAT). Statistically significant correlations were found between DPP® CVL development time and clinical status, culture status, circulating DNA levels, and IFAT titer. DPP® CVL results correlated with both clinical severity of disease and serological evidence of asymptomatic L. infantum infection. By precisely documenting the minimum time required for the development of a clear positive result in DPP® CVL, this test could be used in a rapid, semi-quantitative manner for the evaluation of asymptomatic and symptomatic CVL. Our results also indicate that a similar test could be used to improve our understanding of human VL.

United States

Fluorescent Antibody Technique - methods

Real-Time Polymerase Chain Reaction - methods

Asymptomatic Diseases

Leishmaniasis, Visceral - pathology

Dog Diseases - pathology

Antibodies, Protozoan - blood

Leishmaniasis, Visceral - veterinary

Animals

Leishmania infantum - isolation & purification

Time Factors

Diagnostic Tests, Routine - methods

Dogs

Leishmaniasis, Visceral - parasitology

Dog Diseases - diagnosis

Blood - parasitology

Chromatography, Affinity - methods

DNA, Protozoan - blood

Dog Diseases - parasitology

Leishmaniasis, Visceral - diagnosis

Details

Title: Subtitle: Semi-quantitative measurement of asymptomatic L. infantum infection and symptomatic visceral leishmaniasis in dogs using Dual-Path Platform® CVL
Creators: Mandy Larson - Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA
Angela Toepp - Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA
Benjamin Scott - Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA
Melissa Kurtz - Immunology Program, Department of Internal Medicine and Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA
Hailie Fowler - Immunology Program, Department of Internal Medicine and Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA
Javan Esfandiari - Chembio Diagnostic Systems, Inc., 3661 Horseblock Road, Medford, NY, 11763, USA
Randall F Howard - Infectious Disease Research Institute, 1616 Eastlake Ave E., Suite 400, Seattle, WA, 98102, USA
Aarthy C Vallur - Infectious Disease Research Institute, 1616 Eastlake Ave E., Suite 400, Seattle, WA, 98102, USA
Malcolm S Duthie - Infectious Disease Research Institute, 1616 Eastlake Ave E., Suite 400, Seattle, WA, 98102, USA
Christine Petersen - Department of Epidemiology, University of Iowa College of Public Health, S429 CPHB, 145 N. Riverside Dr, Iowa City, IA, 52241, USA. christine-petersen@uiowa.edu
EPID:158:001
Resource Type: Journal article
Publication Details: Applied microbiology and biotechnology, Vol.101(1), pp.381-390
DOI: 10.1007/s00253-016-7925-6
PMID: 27796441
PMCID: PMC6500589
NLM abbreviation: Appl Microbiol Biotechnol
ISSN: 0175-7598
eISSN: 1432-0614
Publisher: Germany
Grant note: R01 TW010500 / FIC NIH HHS
Language: English
Date published: 01/2017
Academic Unit: Epidemiology; Internal Medicine
Record Identifier: 9983995123002771

Metrics

25 Record Views

15 Times Cited - Web of Science